Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18....read more




